RT Journal Article
SR Electronic
T1 Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 269
OP 274
DO 10.21873/anticanres.16159
VO 43
IS 1
A1 TOMISAKI, IKKO
A1 HARADA, MIRII
A1 SAKANO, SHIGERU
A1 TERADO, MICHIKAZU
A1 HAMASUNA, RYOICHI
A1 HARADA, SHUJI
A1 MATSUMOTO, HIROOMI
A1 AKASAKA, SOICHIRO
A1 NAGATA, YUJIRO
A1 MINATO, AKINORI
A1 HARADA, KEN-ICHI
A1 FUJIMOTO, NAOHIRO
YR 2023
UL http://ar.iiarjournals.org/content/43/1/269.abstract
AB Background/Aim: We aimed to clarify the association between body mass index (BMI) and clinical outcomes of pembrolizumab treatment for advanced urothelial cancer (UC). Patients and Methods: We retrospectively reviewed the records of patients with advanced UC who received pembrolizumab after chemotherapy between March 2018 and December 2021. Patients were divided according to BMI into the non-overweight group (BMI <25 kg/m2) and the overweight group (BMI ≥25 kg/m2). We compared the two groups’ tumour response, survival rates, and incidence of immune-related adverse events (irAEs) and investigated the factors predicting survival. Results: Of 84 eligible patients, 63 (75%) and 21 (25%) were in the non-overweight and overweight groups, respectively. Although the objective response rate was higher in the overweight group (55%) than that in the non-overweight group (29%), the difference was not significant. Progression-free survival (PFS) was significantly longer in the overweight group (median 15.2 months) than that in the non-overweight group (median 4.8 months; p=0.01). Overall survival was also longer in the overweight group (median 36.1 months) compared to that in the non-overweight group (13.4 months), but the difference was not significant (p=0.11). Multivariable analysis showed that overweight was significantly associated with favourable PFS. Any and severe (grade 3) irAEs were observed in 15 (24%) and 5 (7.9%) patients in the non-overweight group, respectively, and in 8 (38%) and 2 (9.5%) patients in the overweight group, respectively, but the differences were not significant. Conclusion: BMI was associated with oncological outcomes in patients with advanced UC who received pembrolizumab but not with the development of irAEs.